DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Continuous Glucose Monitoring in Pregnant Women Undergoing Betamethasone Therapy

Information source: Stanford University
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Pregnancy Complications

Intervention: Dexcom Seven Plus Continuous Glucose Monitoring System (Device)

Phase: N/A

Status: Completed

Sponsored by: Stanford University

Official(s) and/or principal investigator(s):
Yasser Yehia El-Sayed, Principal Investigator, Affiliation: Stanford University

Summary

We hope to clarify how betamethasone affects glucose levels in the mother in the days after receiving the drug. This understanding will hopefully allow us to better anticipate the risk of maternal hyperglycemia and therefore establish more appropriate monitoring of maternal glucose to prevent maternal and neonatal complications of hyperglycemia.

Clinical Details

Official title: Continuous Glucose Monitoring in Pregnant Women Undergoing Betamethasone Therapy

Study design: Observational Model: Cohort, Time Perspective: Prospective

Primary outcome: Episodes of hyperglycemia

Secondary outcome: Neonatal hypoglycemia

Detailed description: Pregnant patients who are undergoing inpatient betamethasone therapy as part of their clinical care will be eligible for the study. Once the clinical team and patients have agreed to pursue betamethasone therapy, the patients' treating physician or nurse will inquire if the patient is interested in participating in our study protocol. Those patients who are interested in participation will be consented by either a member of the treatment team or the study team. Prior to receiving the first betamethasone dose, a soft sensor for continuous glucose monitoring system (CGMS) will be inserted superficially under the skin. For those patients who will be receiving a scheduled course of betamethasone, the sensor may be inserted up to 24 hours prior to the betamethasone administration. The patient will be instructed on how to wear and care for the device. She will wear the CGMS for the duration of her hospitalization or for up to 7 days total, whichever time period is shorter. For those patients who are diabetic, they will receive normal finger stick blood glucose (FSBG) monitoring and insulin therapy as determined by their treating physicians. Those patients who are not diabetic will need to have 2 FSBG checks each day to correlate with the device. Abnormal values will be reported to the patients' treating physician and addressed by the treating physician. Prior to being discharged from the hospital, the patient will have the device removed. The patient will otherwise be treated routinely. We will record baseline demographic information and medical history from each of the women. We will also record information from the neonates' newborn medical records.

Eligibility

Minimum age: 18 Years. Maximum age: 50 Years. Gender(s): Female.

Criteria:

Inclusion Criteria:- 18 years of age or older

- Receiving betamethasone as part of routine clinical care.

- Pregnancy between 23+5 and 35+0 weeks

Exclusion Criteria:- Less than 18 years old.

- Major fetal anomalies

- Use of steroid medications in the past 2 weeks.

Locations and Contacts

Stanford University School of Medicine, Stanford, California 94305, United States
Additional Information

Maternal glucose response to betamethasone administration

Starting date: July 2010
Last updated: March 30, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017